Comparison of Dapagliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized,Open-Label, Active-Controlled Trial

Comparison of Dapagliflozin and Pioglitazone Effects on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Patients With Type 2 Diabetes: A Randomized,Open-Label, Active-Controlled Trial - Comparison of Dapagliflozin and Pioglitazone Effects on NAFLD and NASH in Patients With Type 2 Diabetes: A Randomized Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030548

Enrollment

100

Registered

2017-12-25

Start date

2015-09-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

type 2 diabetes mellitus, NAFLD, NASH

Interventions

Dapagliflozin 5 mg/day, 104 weeks Pioglitazone 15-30 mg/day, 104 weeks

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: HbA1c= or > 6.5%

Exclusion criteria

Exclusion criteria: Patients with diabetes complications

Design outcomes

Primary

Measure	Time frame
HbA1c, hepatic attenuation compared with spleen on CT scan imaging	—

Countries

Japan

Contacts

Public ContactNobuaki Nakayama

Saitama Medical University Department of gastroenterology and hepatology

nobunaka@saitama-med.ac.jp049-276-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026